Desentum reports strong safety and immunological data from Phase 1 clinical study with investigational birch pollen allergy vaccine DM-101PX

by kati.sallinen@desentum.fi | Apr 2, 2025 | News

Desentum Oy, a clinical-stage biopharmaceutical company developing novel immuno­therapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch...

Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajille

by kati.sallinen@desentum.fi | Jan 31, 2025 | News

Desentum Oy:n (“Yhtiö”) yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Exu Capital Oy on myynyt yhteensä 6000 B-osaketta (“Osakkeet”) 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä on...

Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland

by kati.sallinen@desentum.fi | Jun 10, 2024 | News

Pekka Mattila, CEO of Desentum was conferred as Honorary Doctor at the University of Eastern Finland on Jun 7, 2024. The Faculty of Science, Forestry and Technology stated the following: “In 2011, Pekka Mattila and researchers from the Department of Chemistry at the...

Desentum raised 12 million euros for advancing allergy vaccine development

by raikeeoy | Feb 8, 2024 | News

Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...

Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Nov 27, 2023 | News

Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started. DM-101-C-002 is a randomised,...

First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

by kapu@raikee.fi | Oct 13, 2023 | News

Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic...